Moderna (MRNA) Short-term Investments (2017 - 2026)

Moderna has reported Short-term Investments for 10 years, with the latest figure at $3.4 billion in Q2 2026.

• Short-term Investments for Q2 2026 came in at $3.4 billion, down 11.34% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.4 billion (down 11.34% YoY), and the FY2025 annual result was $3.2 billion, down 37.15% from the prior year.
• Short-term Investments advanced to $3.4 billion in Q2 2026, from $3.3 billion in the prior quarter.
• Over five years, Short-term Investments peaked at $6.7 billion in Q4 2022 and troughed at $3.2 billion in Q4 2025.
• A 5-year average of $4.8 billion and a median of $5.0 billion in 2022 frame the typical range for Short-term Investments.
• The widest annual swing landed in 2022, when Short-term Investments soared 120.98%; it then tumbled 37.15% in 2025.
• A 5-year view of Short-term Investments shows it stood at $6.7 billion in 2022, then fell by 14.93% to $5.7 billion in 2023, then declined by 10.51% to $5.1 billion in 2024, then tumbled by 37.15% to $3.2 billion in 2025, then grew by 6.59% to $3.4 billion in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $3.4 billion in Q2 2026, $3.3 billion in Q1 2026, and $3.2 billion in Q4 2025.